Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
April 2017
-
Loss of friend to liver cancer sharpens focus on experimental therapy
A Novartis experimental drug in clinical trial aims to block liver cancer growth
-
Media ReleaseNovartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
March 2017
-
Women in Science: Annie Martin
Our Global Head of Precision Medicine in Oncology discusses her day-to-day work at Novartis.
-
Media ReleaseNovartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority ReviewPriority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the…
-
Could digital technology drive clinical research in Africa?
Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.
-
Eyewitness to a healer pursues new treatments for patients
Inspired by her mother, Vicky Qi leads drug discovery teams.
-
Media ReleaseAlcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correctionThe unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses…
-
Striving to vanquish leukemia
Combination of two compounds shows promise in the lab
-
Media ReleaseNovartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failurePhase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…
-
Media ReleaseNovartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasisNew data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Media ReleaseNew analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetesNew post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
-
Media ReleaseNovartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitorApproved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
Pagination
- ‹ Previous page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- …
- 152
- › Next page